A newly developed radiotracer called 99mTc-p5+14 has been found to generate high-quality images of cardiac amyloidosis, a condition known as the "Alzheimer's disease of the heart." This radiotracer, designed for planar and SPECT/CT imaging, could play a crucial role in the early detection and treatment of cardiac amyloidosis. Currently, there are no FDA-approved imaging agents for detecting the condition. The first-in-human study of this radiotracer showed that it produced high-quality and easily interpretable images, with significant uptake observed in the hearts of patients with amyloid cardiomyopathy. The radiotracer is currently undergoing evaluation in clinical trials to assess its safety and efficacy. The data and insights obtained will support a Phase 3 study and eventual FDA approval submissions.
Mon, 10 Jun 2024 19:12:15 GMT | EurekAlert